Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355115 | 0.89 | CXCR2 (0.46) | CXCR2CCR7 | |
| SCHEMBL3856241 | 0.83 | CXCR2 (0.61) | CXCR2CCR7 | |
| SCHEMBL3852998 | 0.79 | CXCR2 (0.52) | CXCR2CCR7 | |
| SCHEMBL3860775 | 0.74 | CXCR2 (0.66) | CXCR2CCR7 | |
| SCHEMBL3852213 | 0.73 | CXCR2 (0.48) | CXCR2CCR7 | |
| SCHEMBL3857600 | 0.72 | CXCR2 (0.61) | CXCR2CCR7 | |
| SCHEMBL7004456 | 0.69 | CXCR2 (0.75) | CXCR2CCR7 | |
| SCHEMBL3857594 | 0.68 | CXCR2 (0.86) | CXCR2CCR7 | |
| SCHEMBL7595789 | 0.68 | CXCR2 (0.86) | CXCR2CCR7 | |
| SCHEMBL6352130 | 0.68 | CXCR2 (0.36) | CXCR2CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958344-B2 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-10-25 | — | — | US | disclosed |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-10-20 | — | — | US | disclosed |
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1265899-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001058902-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040523-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CCR5, CXCR1, CXCR4 | CXCR2 4/4885CCR7 13/4885 |
| US-20050234077-A1 | Pyrimidine compounds and their use as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR2 | CXCR2 3/4885CCR7 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.